On-demand Webinar
Understanding the intricate biological mechanisms of the liver is critical to facilitate novel therapies for unsolved liver pathologies. For this, complex and scalable 3D in vitro models are needed to recapitulate the physiological relevance and complexity of human liver tissue. However, most microphysiological systems aiming to mimic liver tissue and disease do not yield human relevance, failing to accommodate multi-cell modeling and subsequently often resulting in forceful confinement of various cell types in different channels by the means of artificial membranes within the system.
We developed a comprehensive and robust liver model that is biologically representative of the organ’s composition, function and structure. With its suitability for automation and high-throughput screening, it has the capacity to pave the way for substantial progress in novel therapies against infectious diseases and cancer.
Watch our webinar to hear our speaker Flavio Bonanini, Scientist at MIMETAS, presenting about liver tissue and disease modeling capabilities at MIMETAS, and how our developed model may be used for an array of applications, highlighting its unprecedented versatility and physiological relevance.
In this webinar, you will:
- Learn about state-of-the-art, 3D in vitro liver tissue and disease modeling incorporating multiple cell types, including hepatocytes, liver endothelial cells, stellate cells and immune cells
- Explore key applications of our liver model, including fibrosis, steatosis and other metabolic assays
- Discover key findings of a fully automated and multiplexed anti-fibrotic drug screening project
Access the recording here
Speaker
Flavio Bonanini is a Scientist at MIMETAS and recently finished his Marie Sklodowska-Curie 
fellowship at the PoLiMeR consortium. Previously, he studied biology and biomedical engineering, specializing in tissue engineering at the Swiss Federal Institute of Technology (ETH) in Zurich. In his current role, he focuses on establishing and developing liver models in the OrganoPlate, MIMETAS high throughput organ-on-chip platform.
